The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), for the treatment of first-line metastatic triple negative breast cancer (mTNBC).
 
Fei Ma
Research Funding - Shanghai Escugen Biotechnology
 
Fuming Qiu
No Relationships to Disclose
 
Zhongsheng Tong
No Relationships to Disclose
 
Yehui Shi
No Relationships to Disclose
 
Guohua Yu
No Relationships to Disclose
 
Xinhong Wu
No Relationships to Disclose
 
Hong Wang
No Relationships to Disclose
 
Jiani Wang
No Relationships to Disclose
 
Hua Yang
No Relationships to Disclose
 
Anwen Liu
No Relationships to Disclose
 
Yan Zhang
No Relationships to Disclose
 
Hongmei Zheng
No Relationships to Disclose
 
Qiongyu Lan
No Relationships to Disclose
 
Yongqiang Zhang
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Qing Zhou
Employment - Shanghai Escugen Biotechnology
Leadership - Shanghai Escugen Biotechnology
Stock and Other Ownership Interests - Shanghai Escugen Biotechnology
Patents, Royalties, Other Intellectual Property - Shanghai Escugen Biotechnology
Travel, Accommodations, Expenses - Shanghai Escugen Biotechnology
 
Xiaoyan Xing
Employment - Shanghai Escugen Biotechnology
Leadership - Shanghai Escugen Biotechnology
Travel, Accommodations, Expenses - Shanghai Escugen Biotechnology
 
Xiaomei Chen
Employment - Shanghai Escugen Biotechnology
Travel, Accommodations, Expenses - Shanghai Escugen Biotechnology